SURMOUNT-5
In SURMOUNT-5, published in the New England Journal of Medicine in 2025, 751 adults with obesity but without type 2 diabetes took the highest dose they could tolerate of tirzepatide (10 or 15 mg, the medicine in Zepbound) or semaglutide (1.7 or 2.4 mg, the medicine in Wegovy), once a week for 72 weeks.
Weight fell by an average of 20.2% on tirzepatide and 13.7% on semaglutide. Waist size fell by 18.4 cm and 13.0 cm.
The most common side effects in both groups were stomach-related, mostly mild to moderate, and mostly while the dose was being raised.
Everyone knew which medicine they were taking (an open-label trial), and the trial was funded by Eli Lilly, which makes tirzepatide.